Senior Director-Cytogenetics

About Us

CSI Laboratories, a Fulgent Genetics Company, is a nationally recognized cancer testing and diagnostics laboratory experienced in helping pathologists and oncologists diagnose and treat cancer patients.

Founded in 2011, our parent entity, Fulgent Genetics, has evolved into a premier full-service genomic testing company built around a foundational technology platform.

Through our diverse testing menu, Fulgent is focused on transforming patient care in oncology, anatomic pathology, infectious and rare diseases, and reproductive health. We believe that by providing a wide range of effective, flexible testing options in conjunction with best-in-class service and support, we can redefine the way medicine is managed for patients and clinicians alike.

Since integrating with our therapeutic development business, Fulgent is also developing drug candidates for treating a broad range of cancers using a novel nanoencapsulation and targeted therapy platform. By merging our fields of expertise, we aim to become a fully integrated precision medicine company.

Summary of Position

Responsible for review and sign out of cytogenetic and fluorescent in-situ hybridization (FISH) cases.

Key Job Elements

• Responsible for review and sign out of cytogenetic and FISH cases
• Application of accepted criteria in formulating and reporting diagnostic/prognostic information on various specimens including hematologic and solid tumor specimens.
• Ensure that the reports of test results include pertinent information required for interpretation.
• Collaboration with hematopathologists and surgical pathologists to provide appropriate diagnostic and prognostic interpretation.
• Interpretation/sign-out of pathology specimens within CAP guidelines for turnaround time.
• Provide clinical laboratory consultation to technical personnel and healthcare providers.
• Participation in Quality Assurance measures for the laboratory as required by accreditation standards.
• Provide residents and/or trainees information on specimen evaluation and reporting as needed.
• Provide on-call services as designated in department schedule
• Support with guidance and training of the Genetics analysis technologists, as needed
• Perform other responsibilities as requested or required by CLIA and other local, state, or federal regulations.

Knowledge/Experience

• Doctorate degree (PhD and/or MD) in genetics, molecular genetics, human genetics, or related field.
• ABMGG board-certified in Clinical Cytogenetics, Genetics, or Laboratory Genetics and Genomics.
• 5+ years of relevant director-level experience in clinical cytogenetics.
• Laboratory personnel participating in licensure or certification maintenance programs must complete the number of continuing education hours prescribed by their licensing or certifying agency.
• Technical laboratory personnel whose certification has been grandfathered and does not require participation in a certification maintenance program must complete at least twelve hours of continuing education annually.

Environment

Fulgent Therapeutics LLC is an Equal Employment Opportunity Employer.

The work environment characteristics described here are representative of those an employee encounters while performing the essential functions of this job. Reasonable accommodations may be made to enable qualified individuals with disabilities to perform the essential functions. The term "qualified individual with a disability" means an individual with a disability who, with or without reasonable accommodation, can perform the essential functions of the position.

Please note that Fulgent (and its affiliated companies, including Inform Diagnostics and CSI Laboratories) does not accept unsolicited information and/or resumes from search firms or agencies for our job postings. Search firms or agencies without an applicable contract and/or express approval to recruit for the role in question - that choose to submit a resume or client information to our career page or to any employee of Fulgent - will not be eligible for payment of any fee(s), and any associated shared data will become the property of Fulgent.